Van Andel Institute and Cure Parkinson's have renewed a funding agreement to support the International Linked Clinical Trials ...

Parkinson's disease represents a $6-8 billion market today, projected to exceed $13 billion by the 2030s, driven by rising ...

Symptoms of Parkinson’s disease, such as tremors and stiffness, can make daily tasks difficult. A new drug has shown promise in alleviating symptoms. Tavapadon, a drug being tested to treat early ...

Mouse models of GBA1 Parkinson’s disease that are treated with Gain Therapeutics’ clinical-stage drug appear to have better cognitive function and lower disease biomarkers than untreated animals. The ...

A new anti-inflammatory drug could speed up treatment effectiveness for a neurological disease that 50 Australians are ...

When the hospital germ Pseudomonas aeruginosa infects the body, it uses the sugar-binding protein LecA to attach itself to ...

An experimental Parkinson’s disease drug on its way to AbbVie as part of an $8.7 billion acquisition has met the goals of a pivotal study, setting up the pharmaceutical giant with a drug prospect that ...

An industry-focused, end-to-end meeting covering neurodegenerative R&D from early discovery through late-stage clinical and ...

There are currently no FDA-approved means to prevent or cure Parkinson’s—a disease that afflicts more than 10 million adults worldwide, and is expected to rise to 1.2 million by 2030. Patients usually ...

Scientists are to examine whether drugs that are already in use could be repurposed to treat the symptoms of both Alzheimer’s disease and Parkinson’s in a new collaboration which aims to discover ...

Gain Therapeutics’s (NASDAQ:GANX) is one of the 12 hot penny stocks to invest in right now. At the Society for Neuroscience ...

Taking antiepileptic drugs (AEDs) was associated with a subsequent diagnosis of Parkinson's disease (PD), a U.K.-based case control study suggested. There was a significant association between AED ...